583.24
price down icon0.38%   -2.24
after-market After Hours: 585.00 1.76 +0.30%
loading
Regeneron Pharmaceuticals Inc stock is traded at $583.24, with a volume of 655.36K. It is down -0.38% in the last 24 hours and up +1.72% over the past month. Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
See More
Previous Close:
$585.48
Open:
$587.59
24h Volume:
655.36K
Relative Volume:
0.65
Market Cap:
$60.76B
Revenue:
$14.21B
Net Income/Loss:
$4.46B
P/E Ratio:
14.70
EPS:
39.6877
Net Cash Flow:
$3.56B
1W Performance:
+3.73%
1M Performance:
+1.72%
6M Performance:
+1.83%
1Y Performance:
-41.44%
1-Day Range:
Value
$578.42
$591.45
1-Week Range:
Value
$569.99
$618.01
52-Week Range:
Value
$476.49
$1,024.36

Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile

Name
Name
Regeneron Pharmaceuticals Inc
Name
Phone
(914) 847-7000
Name
Address
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Name
Employee
15,207
Name
Twitter
@regeneron
Name
Next Earnings Date
2025-08-01
Name
Latest SEC Filings
Name
REGN's Discussions on Twitter

Compare REGN with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
583.24 62.05B 14.21B 4.46B 3.56B 39.69
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
410.28 103.30B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
459.58 59.25B 2.46B -319.09M -52.09M -2.4669
Biotechnology icon
ARGX
Argen X Se Adr
797.35 48.22B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
ONC
Beone Medicines Ltd Adr
341.62 37.84B 4.56B -176.77M 225.30M -1.7177

Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades

Date Action Analyst Rating Change
Aug-14-25 Initiated Rothschild & Co Redburn Buy
Jun-30-25 Downgrade Argus Buy → Hold
May-30-25 Downgrade RBC Capital Mkts Outperform → Sector Perform
May-30-25 Downgrade Wells Fargo Overweight → Equal Weight
May-14-25 Upgrade Citigroup Neutral → Buy
Apr-22-25 Resumed Cantor Fitzgerald Overweight
Feb-05-25 Upgrade Leerink Partners Market Perform → Outperform
Jan-16-25 Downgrade UBS Buy → Neutral
Dec-10-24 Resumed BofA Securities Underperform
Nov-15-24 Initiated Wolfe Research Outperform
Nov-14-24 Initiated Citigroup Neutral
Sep-24-24 Downgrade Leerink Partners Outperform → Market Perform
Mar-12-24 Initiated Bernstein Outperform
Jan-12-24 Upgrade RBC Capital Mkts Sector Perform → Outperform
Nov-09-23 Initiated Deutsche Bank Hold
Nov-03-23 Upgrade Raymond James Mkt Perform → Outperform
Aug-21-23 Upgrade Canaccord Genuity Hold → Buy
Aug-21-23 Reiterated Oppenheimer Perform
Jun-28-23 Downgrade Canaccord Genuity Buy → Hold
Mar-27-23 Upgrade SVB Securities Market Perform → Outperform
Mar-24-23 Upgrade Jefferies Hold → Buy
Mar-23-23 Upgrade Raymond James Underperform → Mkt Perform
Jan-30-23 Upgrade Cowen Market Perform → Outperform
Jan-20-23 Upgrade JP Morgan Neutral → Overweight
Oct-26-22 Downgrade Raymond James Mkt Perform → Underperform
Oct-17-22 Downgrade Evercore ISI Outperform → In-line
Sep-09-22 Upgrade Jefferies Underperform → Hold
Sep-09-22 Upgrade Morgan Stanley Equal-Weight → Overweight
Jul-25-22 Downgrade SVB Leerink Outperform → Mkt Perform
Jul-13-22 Initiated Cantor Fitzgerald Neutral
Jun-06-22 Initiated Jefferies Underperform
May-23-22 Initiated SVB Leerink Outperform
Jan-05-22 Downgrade BofA Securities Neutral → Underperform
Jan-03-22 Upgrade Bernstein Mkt Perform → Outperform
Dec-15-21 Downgrade Bernstein Outperform → Mkt Perform
Dec-09-21 Resumed Wells Fargo Overweight
Dec-07-21 Resumed Cowen Market Perform
Dec-06-21 Initiated Goldman Buy
Nov-19-21 Resumed BMO Capital Markets Outperform
Nov-05-21 Downgrade The Benchmark Company Buy → Hold
Jun-29-21 Initiated H.C. Wainwright Buy
Jan-25-21 Upgrade BMO Capital Markets Market Perform → Outperform
Jan-13-21 Upgrade The Benchmark Company Hold → Buy
Jan-08-21 Upgrade Citigroup Neutral → Buy
Oct-05-20 Upgrade Cantor Fitzgerald Neutral → Overweight
Aug-20-20 Downgrade The Benchmark Company Buy → Hold
Jul-09-20 Upgrade SunTrust Hold → Buy
May-26-20 Upgrade Wells Fargo Equal Weight → Overweight
Apr-28-20 Downgrade Citigroup Buy → Neutral
Apr-17-20 Upgrade The Benchmark Company Hold → Buy
Apr-08-20 Initiated The Benchmark Company Hold
Mar-31-20 Initiated Wolfe Research Peer Perform
Feb-27-20 Initiated Barclays Overweight
Feb-26-20 Upgrade Canaccord Genuity Hold → Buy
Feb-26-20 Downgrade Robert W. Baird Outperform → Neutral
Feb-25-20 Upgrade Jefferies Hold → Buy
Feb-11-20 Upgrade Argus Hold → Buy
Dec-24-19 Initiated Raymond James Mkt Perform
Dec-16-19 Downgrade Evercore ISI Outperform → In-line
Dec-13-19 Upgrade Credit Suisse Neutral → Outperform
Nov-12-19 Initiated SunTrust Hold
Nov-07-19 Upgrade Citigroup Neutral → Buy
Oct-17-19 Resumed BofA/Merrill Neutral
Sep-23-19 Upgrade Guggenheim Neutral → Buy
View All

Regeneron Pharmaceuticals Inc Stock (REGN) Latest News

pulisher
07:05 AM

Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Slow Capital Inc. - MarketBeat

07:05 AM
pulisher
Oct 06, 2025

Galderma Punches Above Its Weight Against Dermatology Goliaths - insights.citeline.com

Oct 06, 2025
pulisher
Oct 06, 2025

Regeneron Pharmaceuticals (REGN): Valuation in Focus Following Breakthrough Pipeline Results and Expanded Drug Approvals - simplywall.st

Oct 06, 2025
pulisher
Oct 06, 2025

Strategies to average down on Regeneron Pharmaceuticals Inc.2025 Top Gainers & Smart Investment Allocation Tips - newser.com

Oct 06, 2025
pulisher
Oct 06, 2025

Regeneron (REGN) Projects $83 Million R&D Charge in Q3 2025 - GuruFocus

Oct 06, 2025
pulisher
Oct 06, 2025

Regeneron expects $83 million IPR&D charge in third quarter 2025 results - Investing.com

Oct 06, 2025
pulisher
Oct 06, 2025

Top chart patterns to watch in Regeneron Pharmaceuticals Inc.Earnings Miss & Advanced Technical Signal Analysis - newser.com

Oct 06, 2025
pulisher
Oct 06, 2025

Can trapped investors hope for a rebound in Regeneron Pharmaceuticals Inc.Earnings Summary Report & Weekly High Potential Alerts - newser.com

Oct 06, 2025
pulisher
Oct 06, 2025

Is Regeneron Pharmaceuticals Inc. stock resilient to inflationQuarterly Market Review & Verified Technical Trade Signals - newser.com

Oct 06, 2025
pulisher
Oct 06, 2025

111 Capital Makes New $517,000 Investment in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Oct 06, 2025
pulisher
Oct 06, 2025

J. Safra Sarasin Holding AG Sells 438 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Oct 06, 2025
pulisher
Oct 06, 2025

Janney Montgomery Scott LLC Has $6.61 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Oct 06, 2025
pulisher
Oct 06, 2025

Published on: 2025-10-06 01:04:19 - newser.com

Oct 06, 2025
pulisher
Oct 05, 2025

Marietta Wealth Management LLC Has $6.01 Million Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Oct 05, 2025
pulisher
Oct 05, 2025

Why pension funds invest in Regeneron Pharmaceuticals Inc. (RGO) stock2025 Support & Resistance & Daily Risk Controlled Trade Plans - newser.com

Oct 05, 2025
pulisher
Oct 05, 2025

Applying Elliott Wave Theory to Regeneron Pharmaceuticals Inc.Weekly Stock Recap & Accurate Buy Signal Alerts - newser.com

Oct 05, 2025
pulisher
Oct 05, 2025

Why millennials buy Regeneron Pharmaceuticals Inc. (RGO) stockRisk Management & Expert Approved Momentum Trade Ideas - newser.com

Oct 05, 2025
pulisher
Oct 04, 2025

Why Regeneron (REGN) Is Up 6.4% After FDA Expansion and Positive Late-Stage Trial Results - simplywall.st

Oct 04, 2025
pulisher
Oct 04, 2025

Mirae Asset Global Investments Co. Ltd. Grows Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Oct 04, 2025
pulisher
Oct 04, 2025

Robeco Institutional Asset Management B.V. Trims Stock Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Oct 04, 2025
pulisher
Oct 04, 2025

Truist Financial Corp Decreases Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Oct 04, 2025
pulisher
Oct 03, 2025

Regeneron Pharmaceuticals catalysts could drive stock higher: analysts - Proactive financial news

Oct 03, 2025
pulisher
Oct 03, 2025

Forecasting Regeneron Pharmaceuticals Inc. price range with options data2025 Buyback Activity & Weekly Return Optimization Alerts - newser.com

Oct 03, 2025
pulisher
Oct 03, 2025

Greenwood Capital Associates LLC Acquires 4,419 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Oct 03, 2025
pulisher
Oct 03, 2025

Does Regeneron’s 8% Weekly Surge Signal a Shift After New FDA Drug Approval? - simplywall.st

Oct 03, 2025
pulisher
Oct 03, 2025

Regeneron Pharmaceuticals, Inc. $REGN Stock Position Cut by Greenleaf Trust - MarketBeat

Oct 03, 2025
pulisher
Oct 03, 2025

Applying chart zones and confluence areas to Regeneron Pharmaceuticals Inc.Analyst Downgrade & Fast Entry High Yield Stock Tips - newser.com

Oct 03, 2025
pulisher
Oct 02, 2025

Feds Eye Partial Pretrial Ruling In Regeneron FCA Case - Law360

Oct 02, 2025
pulisher
Oct 02, 2025

Regeneron (REGN) Highlights Benefits of Semaglutide and Trevogrumab in Obesity Management - Yahoo Finance

Oct 02, 2025
pulisher
Oct 02, 2025

Formycon secures settlement and license agreement with Regeneron - The Pharma Letter

Oct 02, 2025
pulisher
Oct 02, 2025

Regeneron Pharmaceuticals, Inc. (REGN) Draws Attention With Rare Disease Breakthrough - Insider Monkey

Oct 02, 2025
pulisher
Oct 02, 2025

Q3 Earnings Forecast for REGN Issued By Leerink Partnrs - MarketBeat

Oct 02, 2025
pulisher
Oct 02, 2025

Regeneron (REGN) Gets a Buy from Leerink Partners - The Globe and Mail

Oct 02, 2025
pulisher
Oct 02, 2025

Hudson Value Partners LLC Acquires Shares of 759 Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Oct 02, 2025
pulisher
Oct 02, 2025

Why Regeneron is giving away sequencing “for free”, with Alison Fenney - pharmaphorum

Oct 02, 2025
pulisher
Oct 02, 2025

Formycon secures U.S. License Date for proposed Aflibercept Biosimilar FYB203 following settlement and license agreement with Regeneron - MarketScreener

Oct 02, 2025
pulisher
Oct 01, 2025

Regeneron Pharmaceuticals Inc. (REGN) Reports Positive Results from Several Late-Stage Trials - Yahoo Finance

Oct 01, 2025
pulisher
Oct 01, 2025

The Best Biotech Stocks to Buy - Morningstar

Oct 01, 2025
pulisher
Oct 01, 2025

Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price Up 6.9%Here's Why - MarketBeat

Oct 01, 2025
pulisher
Oct 01, 2025

Red Biotechnology Market Size, Analysis, Trends | Leading - openPR.com

Oct 01, 2025
pulisher
Oct 01, 2025

Leerink Partnrs Analysts Lower Earnings Estimates for REGN - MarketBeat

Oct 01, 2025
pulisher
Oct 01, 2025

Generali Investments CEE investicni spolecnost a.s. Acquires 540 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Oct 01, 2025
pulisher
Oct 01, 2025

PGGM Investments Acquires 51,900 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Oct 01, 2025
pulisher
Oct 01, 2025

Regeneron’s Evkeeza Receives FDA Approval to Treat HoFH in Children Aged 1 to Less Than 5 - Insider Monkey

Oct 01, 2025
pulisher
Sep 30, 2025

What Makes Regeneron Pharmaceuticals (REGN) an Attractive Investment Opportunity? - MSN

Sep 30, 2025
pulisher
Sep 30, 2025

Regeneron: Growth Catalysts Incoming (NASDAQ:REGN) - Seeking Alpha

Sep 30, 2025
pulisher
Sep 30, 2025

Regeneron Pharmaceuticals, Inc. to Report Third Quarter 2025 Financial Results on October 28, 2025 - Quiver Quantitative

Sep 30, 2025
pulisher
Sep 30, 2025

Regeneron to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on October 28, 2025 - The Manila Times

Sep 30, 2025
pulisher
Sep 30, 2025

Major Biotech Earnings Alert: Regeneron Pharmaceuticals Q3 2025 Results Coming October 28 Before Market Open - Stock Titan

Sep 30, 2025
pulisher
Sep 30, 2025

Regeneron Sues Biosimilar Maker Over IP Rights Exemption - Law360

Sep 30, 2025
pulisher
Sep 30, 2025

Regeneron Deal Clears Formycon’s Eylea Biosimilar for Late 2026 - Bloomberg Law News

Sep 30, 2025

Regeneron Pharmaceuticals Inc Stock (REGN) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$459.58
price up icon 1.68%
$797.35
price up icon 1.19%
biotechnology ONC
$341.62
price down icon 0.84%
$162.32
price up icon 2.55%
$106.06
price up icon 0.86%
Cap:     |  Volume (24h):